Not sure if this has come up before.
This company is focused on improving SCT for bone cancers with a new agent, Orca-T.
orcabio.com/clinical-programs/
A phase 2 trial for MF had this result among others:
"Regression of marrow fibrosis to MF grade 0 or 1 was noted by D+ 100 in 7 of 7 Orca-T recipients but only in 1 of 6 SOC patients."
sciencedirect.com/science/a...
100% of (small sample) is neat. Other MF results were also promising.
They are also working on AML, although MPN related AML is unique. But maybe any AML can benefit:
For mostly AML: "The rate of chronic GVHD at 1 year was 5%... vs 38% ..." That is a big advantage.
--
Here is the ph3 clinical trial that includes AML, not clear whether MPN emergent AML is included:
clinicaltrials.gov/ct2/show...
--
They have a newer therapy, Orca-Q, that may allow less matched donors.